Pfizer (NYSE:PFE) Given New $28.00 Price Target at Cantor Fitzgerald

Pfizer (NYSE:PFE) had its target price hoisted by analysts at Cantor Fitzgerald from $27.00 to $28.00 in a report released on Thursday, Benzinga reports. The brokerage currently has a “neutral” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target points to a potential upside of 0.13% from the stock’s current price.

Several other equities research analysts have also recently issued reports on the stock. Weiss Ratings raised shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, August 31st. Scotiabank increased their price target on Pfizer from $30.00 to $33.00 and gave the stock an “outperform” rating in a report on Tuesday. Guggenheim cut their target price on Pfizer from $35.00 to $31.00 and set a “buy” rating on the stock in a research report on Friday, August 7th. JPMorgan Chase & Co. reduced their price target on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating on the stock in a research report on Wednesday, July 8th. Finally, Bank of America decreased their target price on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Friday, July 10th. Five analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $28.61.

Pfizer Stock Up 1.7%

Pfizer stock opened at $27.96 on Thursday. The stock has a market capitalization of $159.39 billion, a PE ratio of 36.80, a price-to-earnings-growth ratio of 1.85 and a beta of 0.32. Pfizer has a 12 month low of $23.62 and a 12 month high of $29.21. The business has a 50 day simple moving average of $27.56 and a 200-day simple moving average of $26.48. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The firm had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same quarter last year, the firm posted $0.78 EPS. The business’s revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, analysts anticipate that Pfizer will post 2.98 EPS for the current fiscal year.

Institutional Investors Weigh In On Pfizer

Hedge funds and other institutional investors have recently modified their holdings of the stock. Vann Equity Management LLC purchased a new position in shares of Pfizer during the 3rd quarter worth approximately $325,000. City Center Advisors LLC acquired a new position in shares of Pfizer in the 3rd quarter valued at $202,000. Winebrenner Capital Management LLC acquired a new position in shares of Pfizer in the 3rd quarter valued at about $211,000. Martin Capital Partners LLC increased its position in shares of Pfizer by 1.9% in the third quarter. Martin Capital Partners LLC now owns 192,106 shares of the biopharmaceutical company’s stock worth $5,479,000 after acquiring an additional 3,555 shares in the last quarter. Finally, Elevation Wealth Partners LLC lifted its stake in shares of Pfizer by 49.3% during the third quarter. Elevation Wealth Partners LLC now owns 2,541 shares of the biopharmaceutical company’s stock worth $72,000 after purchasing an additional 839 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA approved Pfizer’s TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab as a front-line maintenance treatment for adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction therapy. The expanded indication gives Pfizer earlier access to patients in the metastatic-treatment pathway and could broaden TUKYSA’s commercial opportunity. Pfizer’s TUKYSA Gets FDA Nod for Front-Line HER2+ Breast Cancer Maintenance
• Positive Sentiment: Pfizer reported positive Phase 3 results for oral LITFULO in nonsegmental vitiligo, showing meaningful facial and total-body repigmentation with a favorable tolerability profile. Planned regulatory submissions could expand the drug’s use and strengthen Pfizer’s immunology portfolio. Pfizer Posted Positive Phase 3 Vitiligo Results for LITFULO
• Positive Sentiment: The board declared a quarterly dividend of $0.43 per share, or $1.72 annualized, payable December 7 to shareholders of record November 6. The sizable yield may help support demand for PFE among income-oriented investors. Pfizer Declares $0.43 Fourth-Quarter Dividend
• Neutral Sentiment: Pfizer plans to cut approximately 330 jobs at its Sicily, Italy, plant. The move may reduce costs as part of broader restructuring, but it also highlights pressure to streamline operations. Pfizer to Cut Around 330 Jobs in Italy
• Negative Sentiment: Investor commentary remains cautious because Pfizer faces a challenging growth period, recently reported a quarterly loss, and has paid dividends well above reported earnings in some periods. Analysts are also watching competition to the Prevnar vaccine franchise, which generated substantial revenue for Pfizer. Pfizer Stock: Buy, Sell, or Hold?

Pfizer Company Profile

Pfizer Inc (NYSE:PFE) is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research and commercial activities focus on areas including oncology, inflammation and immunology, internal medicine, hospital care and vaccines.

The company’s portfolio includes widely used products such as the Prevnar family of pneumococcal vaccines, Ibrance for certain breast cancers, Eliquis for preventing blood clots, Xeljanz for inflammatory conditions, and Vyndaqel for transthyretin amyloidosis.